Total submissions: 3
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Baylor Genetics | RCV001333601 | SCV001526239 | uncertain significance | Neutral 1 amino acid transport defect | 2018-12-07 | criteria provided, single submitter | clinical testing | This variant was determined to be of uncertain significance according to ACMG Guidelines, 2015 [PMID:25741868]. |
| Fulgent Genetics, |
RCV002499654 | SCV002813297 | uncertain significance | Hyperglycinuria; Neutral 1 amino acid transport defect; Iminoglycinuria | 2022-04-27 | criteria provided, single submitter | clinical testing | |
| Invitae | RCV002546638 | SCV003267782 | uncertain significance | not provided | 2024-01-22 | criteria provided, single submitter | clinical testing | This sequence change replaces threonine, which is neutral and polar, with methionine, which is neutral and non-polar, at codon 180 of the SLC6A19 protein (p.Thr180Met). This variant is present in population databases (rs141487939, gnomAD 0.07%). This variant has not been reported in the literature in individuals affected with SLC6A19-related conditions. ClinVar contains an entry for this variant (Variation ID: 1031693). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt SLC6A19 protein function with a negative predictive value of 80%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |